LivingGLP1
Study S001805

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy - A European Observational Study of Patients With Type 2 Diabetes Initiating Injectable Therapy to Determine Time to Treatment Change, Factors Associated With Treatment Changes and Outcomes Over 24 Months

ClinicalTrials.gov record

Registration

Registration
NCT00635492
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
2515
Start
2008-01
Primary completion
2011-12
Lead sponsor
AstraZeneca
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:exenatide; DRUG:any human insulin or analog insulin(s) given in any regimen by subcutaneous injection
Results posted
TRUE

Registered primary outcomes

  • Estimates of Probability to Remain on Initial Injectable Treatment at 12 and 24 Months. [Month 24]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0040690ORIGINAL RESEARCH Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
Chantal Mathieu
2016Othercites ClinicalTrials.gov:NCT00635492
R0026447Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.
Mathieu C, Diabetes therapy : research, treatment and education of diabetes and related disorders
2013Nonrandomized studyPMID 24018835DOIcites ClinicalTrials.gov:NCT00635492
R0026527Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.
Ostenson CG, Diabetes, metabolic syndrome and obesity : targets and therapy
2013Nonrandomized studyPMID 23667315DOIcites ClinicalTrials.gov:NCT00635492
R0027568Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.
Reaney M, Health and quality of life outcomes
2013Nonrandomized studyPMID 24369764DOIcites ClinicalTrials.gov:NCT00635492; registry reference DERIVED:24369764
R0052919Therapie-assoziierte Faktoren bei Patienten mit Typ-2-Diabetes, die erstmalig mit einem injizierbaren Antidiabetikum behandelt werden sowie deren Behandlungsergebnisse nach 6 Monaten: Die CHOICE-Studie in Deutschland
Matthew D. Reaney, Diabetologie und Stoffwechsel
2012OtherDOIcites ClinicalTrials.gov:NCT00635492